Breaking News Instant updates and real-time market news.

CLVS

Clovis

$35.77

-1.51 (-4.05%)

08:46
10/07/16
10/07
08:46
10/07/16
08:46

Clovis presents efficacy, safety data from NDA population for rucaparib at ESMO

Clovis Oncology announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017. Rucaparib is the Company's oral, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, including those with high genomic loss of heterozygosity also known as "BRCA-like." The current NDA submission seeks approval in patients with tumor BRCA mutations, which includes both germline and somatic mutations. These results demonstrate that rucaparib may represent an important option for women with multiply relapsed BRCA-mutated ovarian cancer based on its encouraging efficacy and tolerability," said Rebecca S. Kristeleit, MD, PhD, The University College London, Cancer Institute, London, UK. "In my opinion, rucaparib has the hallmarks of an important new therapeutic option for ovarian cancer patients." "We are pleased to present the primary efficacy and safety dataset that has been submitted to the FDA as the basis of our NDA for rucaparib in the treatment of advanced ovarian cancer. If approved, rucaparib would be the first PARP inhibitor in the U.S. indicated to treat ovarian cancer patients with germline or somatic BRCA mutations who have received two prior chemotherapies. Women with BRCA mutations represent about 25% of patients in the US living with ovarian cancer," said Patrick J. Mahaffy, CEO and President of Clovis Oncology. "Our NDA review is ongoing with FDA, and in addition we are actively preparing for a European submission during the fourth quarter of 2016."

  • 07

    Oct

  • 06

    Nov

  • 23

    Feb

CLVS Clovis
$35.77

-1.51 (-4.05%)

09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
JANY
09/21/16
DOWNGRADE
JANY
Neutral
Clovis downgraded to Neutral from Buy at Janney Capital
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
10/04/16
PIPR
10/04/16
NO CHANGE
Target $42
PIPR
Neutral
Clovis price target raised to $42 from $14 at Piper Jaffray
Piper Jaffray analyst Steven Breazzano raised his price target for Clovis Oncology (CLVS) to $42 after taking a "comprehensive look" at the PARP inhibitor landscape in ovarian cancer and beyond. The company's PARP inhibitor rucaparib has demonstrated an active profile in ovarian cancer and all signs point to an approval in the 3L+ setting early next year, Breazzano tells investors in a research note. The analyst, however, believes the ultimate key is success in the earlier maintenance setting, and he thinks the race may still be Tesaro's (TSRO) niraparib's to lose. Breazzano keeps a Neutral rating on Clovis.

TODAY'S FREE FLY STORIES

DWDP

DowDuPont

$74.95

-0.46 (-0.61%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
DowDuPont, UC Davis team up to advance orphan African crops »

Dow AgroSciences teamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

, BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
NTN Buzztime digital menu and payment go live at Buffalo Wild Wings »

NTN Buzztime (NTN), has…

NTN

NTN Buzztime

$4.91

0.3 (6.51%)

BWLD

Buffalo Wild Wings

$156.65

-0.1 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$0.87

0.04 (4.82%)

08:02
01/17/18
01/17
08:02
01/17/18
08:02
Hot Stocks
Alliance MMA, FloSports announce event rights fee deal »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSE

Trinseo

$77.45

-1.1 (-1.40%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Recommendations
Trinseo analyst commentary  »

Trinseo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$244.74

0.27 (0.11%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Hot Stocks
3M submits 510(k) application for Attest 24-minute readout »

3M announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

LXFT

Luxoft

$55.35

-1.8 (-3.15%)

08:01
01/17/18
01/17
08:01
01/17/18
08:01
Upgrade
Luxoft rating change  »

Luxoft upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DST

DST Systems

$83.63

0.12 (0.14%)

, SSNC

SS&C

$48.48

-0.99 (-2.00%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Downgrade
DST Systems, SS&C rating change  »

DST Systems downgraded to…

DST

DST Systems

$83.63

0.12 (0.14%)

SSNC

SS&C

$48.48

-0.99 (-2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$17.16

-0.6 (-3.38%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Options
GameStop put buyer realizes 26% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$119.72

0.02 (0.02%)

08:00
01/17/18
01/17
08:00
01/17/18
08:00
Recommendations
Monsanto analyst commentary  »

Monsanto price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

08:00
01/17/18
01/17
08:00
01/17/18
08:00
General news
U.S. chain store sales fell 1.9% to 115.3 in the week ended January 13 »

U.S. chain store sales…

COG

Cabot Oil & Gas

$28.03

-0.85 (-2.94%)

07:59
01/17/18
01/17
07:59
01/17/18
07:59
Downgrade
Cabot Oil & Gas rating change  »

Cabot Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$110.40

-3.54 (-3.11%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Recommendations
Westlake Chemical analyst commentary  »

Westlake Chemical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LADR

Ladder Capital

$14.62

1.03 (7.58%)

07:58
01/17/18
01/17
07:58
01/17/18
07:58
Hot Stocks
Ladder Capital reports unsolicited $15 per share takeover proposal from Related »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

LYB

LyondellBasell

$115.89

-1.79 (-1.52%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Recommendations
LyondellBasell analyst commentary  »

LyondellBasell price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$163.35

-7.35 (-4.31%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Technical Analysis
Technical Take: bluebird bio sharply higher in early trading »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AEP

American Electric

$67.50

0.04 (0.06%)

07:57
01/17/18
01/17
07:57
01/17/18
07:57
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

07:56
01/17/18
01/17
07:56
01/17/18
07:56
Periodicals
iPhone supply chain prepares for low order visibility in 1Q18, DigiTimes says »

Component suppliers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

UNH

UnitedHealth

$232.90

4.26 (1.86%)

07:56
01/17/18
01/17
07:56
01/17/18
07:56
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$109.67

-1.67 (-1.50%)

07:55
01/17/18
01/17
07:55
01/17/18
07:55
Recommendations
Celanese analyst commentary  »

Celanese price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

07:55
01/17/18
01/17
07:55
01/17/18
07:55
General news
Fedspeak resumes along with a Senate vote on Powell »

Fedspeak resumes along…

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

07:54
01/17/18
01/17
07:54
01/17/18
07:54
Downgrade
Continental Resources rating change  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PXD

Pioneer Natural

$182.51

-3.64 (-1.96%)

07:53
01/17/18
01/17
07:53
01/17/18
07:53
Downgrade
Pioneer Natural rating change  »

Pioneer Natural…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

IPAS

iPass

$0.45

-0.0349 (-7.21%)

07:53
01/17/18
01/17
07:53
01/17/18
07:53
Initiation
iPass initiated  »

iPass initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BYD

Boyd Gaming

$36.16

-0.32 (-0.88%)

07:51
01/17/18
01/17
07:51
01/17/18
07:51
Initiation
Boyd Gaming initiated  »

Boyd Gaming initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.